| 标题 |
Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:The Lancet Oncology 作者:Martin F. Kaiser; R. Phillip; Sarah R. Brown; A. Holroyd; Elsa Ferris; et al 出版日期:2026-09-01 |
| 求助人 | |
| 下载 | 暂无链接,等待应助者上传 |
PDF的下载单位、IP信息已删除
(2025-6-4)